help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brunello, A. G.
Right arrow Articles by Weis, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunello, A. G.
Right arrow Articles by Weis, J.
(American Journal of Pathology. 2000;157:1485-1493.)
© 2000 American Society for Investigative Pathology

Regular Articles

Astrocytic Alterations in Interleukin-6/Soluble Interleukin-6 Receptor {alpha} Double-Transgenic Mice

Anna G. Brunello*{dagger}, Jakob Weissenberger*, Andreas Kappeler{ddagger}, Claudio Vallan{ddagger}, Malte Peters§, Stefan Rose-John§ and Joachim Weis*

From the Abteilung Neuropathologie*
and Abteilung Immunpathologie,{ddagger}
Pathologisches Institut, Universität Bern, Bern, Switzerland; Institut für Neuropathologie,{dagger}
Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Aachen, Germany; Abteilung Pathophysiologie,§
1. Medizinische Klinik der Universität Mainz, Mainz, Germany

Interleukin-6 (IL-6), a major cytokine with diverse effects on cells mainly of the immune and hematopoietic systems, has been linked to several neurological disorders such as acquired immune deficiency syndrome dementia, multiple sclerosis, and Alzheimer’s disease. Central nervous system (CNS)-specific expression of IL-6 caused neurodegeneration, massive gliosis, and vascular proliferation in transgenic mice. However, the effects of systemically circulating IL-6 and its receptor IL-6R{alpha} on the CNS are unknown. IL-6R{alpha} is the specific component of the IL-6 receptor system and hence an important co-factor of IL-6. IL-6R{alpha} is bioactive in a membrane-bound and in a soluble (s) form. We investigated the effects of systemically elevated levels of either human IL-6 or human sIL-6R{alpha} or both on the CNS of transgenic mice. Although IL-6 and sIL-6R{alpha} single transgenic mice were free of neurological disease, IL-6/sIL-6R{alpha} double-transgenic mice showed neurological signs, such as tremor, gait abnormalities, and paresis. However, these mice also frequently showed prominent general weakness probably because of the systemic effects of IL-6/IL-6R{alpha} such as liver damage and plasmacytomas. IL-6/sIL-6R{alpha} transgenic mice exhibited massive reactive gliosis. Lack of signs of neuronal breakdown versus ample astrogliosis suggested that astrocytes were selectively affected in these mice. There was neither vascular proliferation nor inflammatory infiltration. Ultrastructural analysis revealed blood-brain barrier (BBB) changes manifested by hydropic astrocytic end-feet. However, albumin immunohistochemistry did not reveal major BBB leakage. Our results indicate that increased and constitutive systemic expression of IL-6 together with its soluble receptor sIL-6R{alpha} is less harmful to the brain than to other organs. The BBB remains primarily intact. IL-6/IL-6R{alpha}, however, might be directly responsible for the selective activation of astrocytes.




This article has been cited by other articles:


Home page
 DiabetesHome page
O. P. Kristiansen and T. Mandrup-Poulsen
Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent?
Diabetes, December 1, 2005; 54(suppl_2): S114 - S124.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.